New role for an old friend: Prednisone is a disease-modifying agent in early rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 15, Issue 3, 2003, Pages 193-196

  Conn, Doyt L ^a,c   Lim, S Sam ^b  

^a Division of Rheumatology   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOOXYGENASE 2; GAMMA INTERFERON; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; VITAMIN D;

BONE INJURY; CATARACT; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG TOLERABILITY; ECCHYMOSIS; FOLLOW UP; HUMAN; LOW DRUG DOSE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PREDNISONE; PROGNOSIS; RISK ASSESSMENT; ROLE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038408686     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200305000-00004     Document Type: Review

References (28)

1. Lim SS, Conn DL: The use of low-dose prednisone in the management of rheumatoid arthritis. Bull Rheum Dis 2001, 50(12):1-4.
2. Moreland LW, O'Dell JR: Glucocorticoids and rheumatoid arthritis. Back to the future? Arthritis Rheum 2002, 46:2553-2563.
3. Saag KG: Resolved: low-dose glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid arthritis. Arthritis Care Res 2001, 45:468-471.
4. Conn DL: Resolved: low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Care Res 2001, 45:462-467.
5. Boers M: Rheumatoid Arthritis: Treatment of early disease. Rheum Dis Clin No Am. Philadelphia: WB Saunders Co; 2001, 27(2).
6. Kirwan JR: Systemic low-dose glucocorticoid treatment in rheumatoid arthritis. Rheum Dis Clin No Am. Philadelphia: WB Saunders, 2001, 27(2).
7. O'Dell JR: How is it best to treat early rheumatoid arthritis patients? Best Practice and Research Clin Rheumatol. New York: Harcourt Publishers, 2001, 15(1):125-137.
8. Zink A, Listing J, Ziemer S, et al.: Practice variation in the treatment of rheumatoid arthritis among German rheumatologists. J Rheumatol 2001, 28(10):2201-2208.
9. Riise T, Jacobsen BK, Gran JR: Changes in the therapy of rheumatoid arthritis during the period 1979 to 1996. 2001, Scand J Rheumatol 30:199-202.
10. Bijlsma JWJ, van Everdingen AA, Huisman M, et al.: Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann NY Acad Sci 2002, 966:82-90. Analysis of four prospective studies showed that low doses of prednisone cause significant reduction in the development and progression of erosions in RA
11. Dougados M, Smolen JS: Pharmacological management of early rheumatoid arthritis: does combination therapy improve outcomes? J Rheumatol 2002, 29(66):20-26.
12. Hench PS, Slocumb CH, Polley HF, et al.: Effect of cortisone and pituitary adrenocorticotropic hormone (ACTH) on rheumatic diseases. JAMA 1950, 144:1327-1335.
13. Ward IE, Polley HF, Power MH, et al.: Prednisone in rheumatoid arthritis: metabolic and clinical effects. Ann Rheum Dis 1958, 17:145-159.
14. Report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis (first report). Ann Rheum Dis 1959, 18:173-187.
15. Auphan N, DiDonato JA, Rosette C, et al.: Immunosuppression by glucocorticoids: inhibition of NF-KB activity through induction of IKB synthesis. Science 1995, 270:286-290.
16. Buttgereit F, da Silva JAP, Boers M, et al.: Standardized nomenclature for glucocorticoids dosages and glucocorticoids treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002, 61:718-722. This is a summary of the first European workshop on glucocorticoid therapy held in 2001. The mechanism of action, dosage, and standardization of timing and dosage was discussed
17. Schuerwegh AJ, van Offel JF, Bridts CH, et al.: Influence of long-term therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CDS+ T lymphocytes of patients with rheumatoid arthritis. J Rheumatol 2001, 28(8):1793-1799.
18. Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis. Viewpoint based on a systemic pathogenetic role. Arthritis Rheum 2001, 44(3): 493-507.
19. Dekkers JC, Geenen R, Godaert GLR, et al.: Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis. J Rheumatol 2001, 28(7):1496-1504. This is a study of the hypothalamic-pituitary-adrenal axis responsiveness in RA
20. Arvidson NG, Gudbjornsson B, Larsson A, et al.: The timing of glucocorticoids administration in rheumatoid arthritis. Ann Rheum Dis 1997, 56:27-31.
21. van Everdingen AA, Jacobs JWG, van Reesema SDR, et al.: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Internal Med 2002, 136(1):1-12. This is a study of the results of a 2-year, randomized, double-blind, placebo-controlled clinical trial of low-dose prednisone in early RA.
22. Landewe RBM, Boers M, Verhoeven AC, et al.: COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46(2):347-356. An analysis of the 5-year effect on radiographic progression in patients with early RAt reared with an initial high dose of prednisone and tapered off by 6 months plus methotrexate and sulfasalazine compared with sulfasalazine alone.
23. Kirwan JR: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995, 333:142-146.
24. Hickling P, Jacoby RK, Kirwan JR: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998, 37:930-936.
25. Doran MF, Crowson CS, Pond GR, et al.: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46(9):2294-2300. This is a study of infections and their predictors in a population-based study of RA.
26. Sambrook P, Raj A, Hunter D, et al.: Osteoporosis with low dose corticosteroids: contribution of underlying disease effects and discriminatory ability of ultrasound versus bone densitometry. J Rheumatol 2002, 28(5):1063-1067.
27. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 update. Arthritis Rheum 2001, 44(7):1496-1503.
28. Klein BEK, Klein R, Lee KE, et al.: Drug use and five-year incidence of age-related cataracts. The Beaver Dam study. Ophthalmology 2001, 108(9):1670-1674.